Lineage Q2 net loss widens to $30.5M on $14.8M impairment; OpRegen 36-mo data positive, cash runway into Q1 2027

Lineage Cell Therapeutics, Inc.

2025-Q2 EPS reported -$0.15 vs consensus -$0.03 ▼ miss (-441.5%)

Q2 2025 revenue $2.8M (+$1.4M YoY); net loss $30.5M ($0.13/sh) vs $5.8M ($0.03) YoY.
Cash $42.3M as of June 30, 2025; expected to fund operations into Q1 2027.
OpRegen: 36-month data shows mean BCVA +6.2 letters (n=10); +9.0 letters in extensive coverage (n=5).
Manufacturing milestone: cGMP production demonstrated for two candidates from cell bank system, scalable to millions of doses.
OPC1: first chronic SCI patient treated in DOSED study using novel delivery system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.